Penapis tumor: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
k analisa → analisis |
Fitur saranan suntingan: 1 pranala ditambahkan. |
||
(2 revisi perantara oleh 2 pengguna tidak ditampilkan) | |||
Baris 2:
{{penyangkalan medis}}
'''Penapis tumor''' adalah suatu tes untuk melakukan penapisan/penyaringan untuk mengetahui kemungkinan adanya tumor/kanker,
Penapis tumor dapat diproduksi secara langsung oleh sel tumor atau bukan sel tumor sebagai akibat adanya tumor. Kebanyakan penapis tumor adalah [[antigen]] tumor, tetapi tidak semua antigen tumor dapat digunakan sebagai penapis tumor.
Meskipun [[mammography]], [[ultrasonography]], [[computed tomography]], [[magnetic resonance imaging]] scans, dan penapis tumor berkala dapat menentukan tingkat beratnya kanker dan tingkat penyembuhan kanker, tetapi penapis tumor bukanlah tes diagnosis yang tentu/pasti. Diagnosis ditegakkan melalui [[biopsi]].<ref name=TumorMarker>{{cite web |url=http://www.cancersafe.com/screening/index.asp |title=Tumor markers Cancer screening |accessdate=December 28, 2013 |archive-date=2019-02-28 |archive-url=https://web.archive.org/web/20190228192302/http://www.cancersafe.com/screening/index.asp |dead-url=yes }}</ref> [[Kolonoskopi]] tanpa pengambilan contoh, juga bukan alat diagnosis, tetapi contoh yang diambil melalui kolonoskopi dan dilakukan biopsi baru dapat dikatakan penegakan diagnosis.
== Penggunaan ==
Baris 34:
* Oesophagus: CEA, Cyfra 21-1
* Thyroid: CEA, NSE
* Paru-paru: CEA, CA 19-9, CA 125, NSE, Cyfra 21-1 (Pada 95% persentil sensivitas Cyfra 21-1 adalah 79%, sedangkan untuk SCC dan CEA adalah 41% dan 31% berturut-turut)<ref>{{cite web |url=http://www.ncbi.nlm.nih.gov/pubmed/9072992 |title=Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis |accessdate=August 6, 2014}}</ref> Ternyata penapis tumor M2-PK juga berguna untuk menapis kanker paru-paru dan lebih baik daripada SCC dan NSE,<ref name="The significance of TU M2-PK tumor">{{cite journal |pmid=17882813 |year=2007 |last1=Oremek |first1=G |last2=Kukshaĭte |first2=R |last3=Sapoutzis |first3=N |last4=Ziolkovski |first4=P |title=The significance of TU M2-PK tumor marker for lung cancer diagnostics |volume=85 |issue=7 |pages=56–8 |journal=Klinicheskaia meditsina}}</ref> sehingga jika diperkirakan masih normal, cukup melakukan penapisan tumor menggunakan M2-PK saja.
* Bladder: CEA, Cyfra 21-1, TPA
Ternyata penapis tumor M2-PK memiliki banyak peran seperti pada: [[kanker usus besar]],<ref name=Haug2007>{{cite journal |doi=10.1038/sj.bjc.6603712 |title=Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients |year=2007 |last1=Haug |first1=U |last2=Rothenbacher |first2=D |last3=Wente |first3=M N |last4=Seiler |first4=C M |last5=Stegmaier |first5=C |last6=Brenner |first6=H |journal=British Journal of Cancer}}</ref> [[kanker payudara]],<ref>{{cite journal |pmid=11326672 |year=2000 |last1=Lüftner |first1=D |last2=Mesterharm |first2=J |last3=Akrivakis |first3=C |last4=Geppert |first4=R |last5=Petrides |first5=PE |last6=Wernecke |first6=KD |last7=Possinger |first7=K |title=Tumor type M2 pyruvate kinase expression in advanced breast cancer |volume=20 |issue=6D |pages=5077–82 |journal=Anticancer research}}</ref><ref>{{cite journal |pmid=20592362 |year=2010 |last1=Benesch |first1=C |last2=Schneider |first2=C |last3=Voelker |first3=HU |last4=Kapp |first4=M |last5=Caffier |first5=H |last6=Krockenberger |first6=M |last7=Dietl |first7=J |last8=Kammerer |first8=U |last9=Schmidt |first9=M |title=The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer |volume=30 |issue=5 |pages=1689–94 |journal=Anticancer research }}</ref> [[renal cell carcinoma]]<ref>{{cite journal |pmid=11326675 |year=2000 |last1=Oremek |first1=GM |last2=Sapoutzis |first2=N |last3=Kramer |first3=W |last4=Bickeböller |first4=R |last5=Jonas |first5=D |title=Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma |volume=20 |issue=6D |pages=5095–8 |journal=Anticancer research}}</ref><ref>{{cite journal |pmid=10470199 |year=1999 |last1=Wechsel |first1=HW |last2=Petri |first2=E |last3=Bichler |first3=KH |last4=Feil |first4=G |title=Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (Tu M2-PK) |volume=19 |issue=4A |pages=2583–90 |journal=Anticancer research}}</ref> [[kanker paru-paru]],<ref name="The significance of TU M2-PK tumor"/><ref>{{cite journal |pmid=12624710 |year=2003 |last1=Schneider |first1=J |last2=Peltri |first2=G |last3=Bitterlich |first3=N |last4=Philipp |first4=M |last5=Velcovsky |first5=HG |last6=Morr |first6=H |last7=Katz |first7=N |last8=Eigenbrodt |first8=E |title=Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients |volume=2 |issue=4 |pages=185–91 |doi=10.1007/s102380300005 |journal=Clinical and experimental medicine
== Referensi ==
|